Novartis Japan Looks To Capitalize On Drug Approval Spurt, Submits NDA For Everolimus
This article was originally published in PharmAsia News
Executive Summary
Novartis Japanese subsidiary Novartis Pharma KK announced Jan. 21 four new drug approvals from Japan's Ministry of Health, Labor and Welfare. The new drugs are approved to treat asthma, hypertension, cancer and age-related macular degeneration